Polymyxin B is a cyclic polypeptide antibiotic primarily used to treat infections caused by Gram-negative bacteria. It is derived from the bacterium Bacillus polymyxa and exhibits a unique structure characterized by a hydrophobic tail and a positively charged peptide ring, which facilitates its interaction with bacterial membranes. This interaction disrupts the integrity of the bacterial cell membrane, leading to cell death. Polymyxin B is particularly effective against multidrug-resistant strains, making it a critical option in clinical settings. However, its use is limited due to potential nephrotoxicity and neurotoxicity, necessitating careful monitoring during treatment. The substance is typically administered via injection or topical application, depending on the type of infection being treated. In addition to its antibacterial properties, Polymyxin B has also been studied for its potential use in other therapeutic areas, including as an adjuvant in certain formulations. Overall, its effectiveness against resistant pathogens underscores its importance in modern medicine, despite the associated risks.

Polymyxin B

1404-26-8: Polymixin B, polimixina B, polymyxine B,  Polymyxine B [INN-French], MeSH ID: D011112,  Polymyxinum B [INN-Latin],  UNII-J2VZ07J96K, Polymyxin B,  Polymyxinum B,  Polimixina B [INN-Spanish]

Chondroitin sulfate sodium (Chondroitin polysulfate sodium) is a natural glycosaminoglycan derived from animal cartilage.

CAS 1404-26-8: Polymyxin B

Polymyxin B

Ref: TM-T78685

Polymyxin B Sulfate

Ref: 3B-P1923